STAT Virtual Event: The Next Frontier of Drug Pricing Reform
Editor’s note: A livestream of the event will be embedded below at 1 p.m. ET….
Category: drug pricing
STAT+: Top federal lobbyist at PhRMA leaves
WASHINGTON — The top federal lobbyist for the brand drug lobby PhRMA is leaving, two…
STAT+: Trade group scolds drugmaker for ‘unethical’ attempt to gain info about rival product
In a notable move, a U.K. trade group has rebuked Leo Pharma for a “serious…
Opinion: The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab
Over the past several months, my conversations with colleagues in the Alzheimer’s field have featured…
STAT+: Key House Republican escalates rhetoric against PBMs
WASHINGTON — A key House Republican ramped up his criticism of pharmacy benefit managers Tuesday,…
STAT+: Sanders wants NIH to adopt ‘reasonable pricing’ language for drugs that agency research helps develop
In another bid to lower prescription drug prices, U.S. Sen. Bernie Sanders (I-Vt.) issued a…
STAT+: Chamber of Commerce tries new legal arguments to challenge Medicare drug-price negotiation
WASHINGTON — The U.S. Chamber of Commerce sued the federal government over its new Medicare drug-price…
Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA
Are drug prices protected by the Constitution? Will Medicare embrace Alzheimer’s disease treatments? And should…
.jpg)
STAT+: ‘We don’t agree’ on drug pricing policy, FDA chief tells biotech leaders
BOSTON — The drug industry has spent the past year speaking against new mechanisms that…
STAT+: Keytruda’s benefits, a breast cancer win, the ‘dom-zim doublet’: Weekend wrap-up from ASCO
CHICAGO — The annual meeting of the American Society of Clinical Oncology is back in…
STAT+: Biotechs face challenges as the industry’s annual bash returns to Boston
The world has changed since 2018 when the Biotechnology Innovation Organization last brought its annual…
STAT+: Republicans want to crack down on pricey health regulations, but there are major loopholes
WASHINGTON — At first glance, the debt ceiling deal that Republicans struck with the White…
STAT+: CVS warns PBM reforms ‘could lead to higher costs’
As Congress considers wide-ranging reforms to pharmacy benefit managers, a top executive at CVS Health,…
STAT+: Gilead and Teva defend antitrust claims that prices for HIV medicines were unfairly kept high
Amid concern that HIV prevention pills are not being widely taken by those at highest…
STAT+: Congress took on high drug prices in Medicare. Now Biden wants to take it to Medicaid
WASHINGTON — The Biden administration wants to help states control Medicaid prescription drug costs by…
STAT+: Congress highlighted a chemo drug’s price to blast PBMs — but it’s not a PBM issue
WASHINGTON — Congress blasted drug middlemen at a hearing Tuesday, with multiple lawmakers pointing to…
.jpg)
STAT+: Supreme Court rules against Amgen in closely watched case over scope of patent claims
In a case that had the pharmaceutical industry on edge, the U.S. Supreme Court upheld…
STAT+: FTC widens probe into pharmacy benefit managers to include group purchasing organizations
The Federal Trade Commission is widening its probe into pharmacy benefit managers and their impact…
STAT+: House panel takes first steps toward reining in hospitals with ‘site-neutral’ changes
WASHINGTON — A key House panel on Wednesday advanced several health care bills on Wednesday,…
STAT+: FTC files lawsuit to block Amgen’s purchase of Horizon Therapeutics
The Federal Trade Commission on Tuesday sued to block Amgen’s $27.8 billion acquisition of Horizon…
AstraZeneca is third member to leave PhRMA in five months
WASHINGTON — AstraZeneca has decided to leave the brand drug lobbying powerhouse PhRMA halfway through…
STAT+: U.S. Supreme Court declines to hear ‘skinny labeling’ case with implications for generic drug access
After months of anticipation, the U.S. Supreme Court declined to hear an appeal of a…
STAT+: Senate panel passes a suite of drug pricing bills — but fails to advance one major PBM reform
WASHINGTON – The Senate health committee on Thursday passed a package of bills aimed at…
Listen: Pharma vs. PBMs, Sarepta at the FDA, & a bold idea gone awry
Is there a Bermuda Triangle of drug prices? Do FDA advisers matter? And when should…
STAT+: Insulin makers, PBMs echo old finger-pointing in Senate hearing
A Senate hearing on high insulin costs billed as a blockbuster showdown with drugmakers and…
STAT+: Pharmalittle: Big pharma maps legal strategy against U.S. drug pricing reform; U.S. pharma layoffs continue to climb
Top of the morning to you, and a fine one it is. The sun is…
STAT+: Q&A: Sen. Sanders on insulin costs and his committee’s generic drug kerfuffle
WASHINGTON — Wednesday’s Senate hearing on high costs for insulin “is not the end” of…
STAT+: EQRX abandons business plan around drug pricing, cuts jobs and programs
EQRx, a company that aimed to lower drug prices by introducing inexpensive me-too medicines, said…
STAT+: NIH grant recipients often fail to disclose agency support in patent applications
The National Institutes of Health may be the largest public funder of biomedical research in…
STAT+: New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced…
STAT+: Disagreements and digs upend an otherwise bipartisan hearing on PBM reform
WASHINGTON — The first Senate health committee markup under Chairman Bernie Sanders (I-Vt.) and ranking…
STAT+: Senators delay start date for possible PBM reforms
WASHINGTON — Pharmacy benefit managers may have gotten themselves a slight reprieve. Senators drafting reforms to…
STAT+: Covid-19 burnished pharma’s reputation among patient groups, but access to medicines is now an issue
In the wake of the Covid-19 pandemic, the pharmaceutical industry enjoyed something of an afterglow,…
STAT+: Medicare official insists drug price negotiation will consider value of drugs
WASHINGTON — When Medicare starts negotiating drug prices, it will take into account how important…
STAT+: Sens. Bernie Sanders, Bill Cassidy reach deal on PBM, generic reform
WASHINGTON — Senate health committee leaders Bernie Sanders and Bill Cassidy on Tuesday announced an agreement…
STAT+: ‘A tug of war’: Europe braces for new legislation with far-reaching impacts on pharma and patients
After more than two years of planning, the European Commission on Wednesday will release long-awaited…
STAT+: Powerful Senate duo drops a bipartisan PBM reform plan
WASHINGTON — The chair and ranking Republican on the Senate Finance Committee on Thursday unveiled…
STAT+: FDA’s Califf talks cell and gene therapies, abortion pill, Alzheimer’s drugs
WASHINGTON — Senators grilled FDA Commissioner Rob Califf Wednesday on everything from the agency’s stance…
STAT+: Senate still hasn’t made hard decisions on lowering insulin costs
WASHINGTON — Senate Democrats are trying to cap insulin costs for every American, but they…
STAT+: PhRMA execs paint grim picture of industry under Medicare drug price negotiation
WASHINGTON — Executives for the brand drug industry’s biggest lobbying group painted a grim picture…
STAT+: Mark Cuban’s drug company creates a pharmacy network to challenge PBMs
In its latest bid to upend the pharmaceutical supply chain, the Mark Cuban Cost Plus…
Opinion: OTC naloxone is a baby step toward making the life-saving medication accessible
In an attempt to make naloxone more accessible amid the massive human toll of the…
STAT+: ‘Style over substance?’ Express Scripts launches new pricing plan amid rising scrutiny of PBMs
Amid increasing scrutiny of pharmacy benefit managers, Express Scripts is launching a new pricing plan…
STAT+: Medicare advisers endorse reforms to lower drug spending
In the latest move to address prescription drug pricing, the Medicare Payment Advisory Commission unanimously…
STAT+: Senate hashing out policy details on generics, PBMs, insulin
WASHINGTON — Senators are slightly delaying their latest legislative push on health care, but as they…
STAT+: Sanders plans to haul insulin executives to testify in Senate
WASHINGTON — Sen. Bernie Sanders plans to call the chief executives of the country’s largest…
STAT+: Brazilian committee says a Vertex cystic fibrosis is not cost-effective and should not be reimbursed
A Brazilian government advisory committee recommended that the health ministry not pay for a cystic…
STAT+: Cancer drug shortages have plagued the U.S. for years. Can they be fixed?
Roughly two million Americans are expected to receive a cancer diagnosis this year. Some members…
STAT+: ‘True disruption’: Mark Cuban’s company will sell brand-name diabetes medicines from Janssen
For the first time, Mark Cuban’s Cost Plus Drug Company is selling medicines made by…
STAT+: A young boy’s nightmare diagnosis, and the $3 million one-time treatment that will likely save his life
When the long-awaited moment arrived, a nurse helped Adam Hess loosen a tiny plastic clamp…